Skip to main content
Neuland Laboratories Limited. logo

Neuland Laboratories Limited. — Investor Relations & Filings

Ticker · NEULANDLAB ISIN · INE794A01010 LEI · 335800AVHZURTYQ17N08 BSE.NS Manufacturing
Open in API
Filings indexed 947 across all filing types
Latest filing 2020-11-26 Regulatory Filings
Country IN India
Listing BSE.NS NEULANDLAB

About Neuland Laboratories Limited.

https://www.neulandlabs.com

Neuland Laboratories Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and provides comprehensive Custom Manufacturing Solutions (CMS). The company focuses on complex chemistry and high-quality standards, operating state-of-the-art manufacturing facilities that comply with international regulatory requirements, including those of the USFDA and EDQM. Its product portfolio spans diverse therapeutic areas such as cardiovascular, central nervous system, anti-infectives, and antiasthmatics. Neuland supports pharmaceutical companies globally through the entire lifecycle of a drug, from early-stage clinical development to commercial-scale production. By leveraging advanced technical expertise and a robust quality management system, the organization delivers reliable chemical synthesis and process optimization services to both innovator and generic drug manufacturers.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding an Analysts / Institutional Investor Meet. It details the date, venue, and participants of the meeting and mentions discussions on general business and information covered during earlier conference calls. There are no financial statements, detailed financial analysis, or earnings data presented. The document is a notification of an investor meeting rather than a full investor presentation or earnings release. Given the nature of the content and the regulatory reference, this fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2020-11-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification to stock exchanges about an Analyst/Institutional Investor meeting held on November 18, 2020. It references Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events or information. The content describes the meeting details and discussions but does not contain any financial statements, detailed financial data, or report content. The document length is short (1527 characters), and it serves as an announcement of the meeting rather than a full report or transcript. Therefore, it fits best under the category of Investor Presentation (IP), as it relates to investor meetings and presentations, but since it is only an intimation of the meeting and not the presentation itself, it is closest to Regulatory Filings (RNS) as a general regulatory announcement. However, given the specific nature of the meeting announcement under SEBI regulations, the best fit is Regulatory Filings (RNS).
2020-11-18 English
Related Party Transactions
Regulatory Filings Classification · 95% confidence The document is a submission to stock exchanges (BSE and NSE) regarding a half yearly disclosure on Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It contains detailed related party transaction data for the half year ended September 30, 2020. The document is not a full interim or quarterly report with comprehensive financial statements but a regulatory disclosure focused on related party transactions. It is not an announcement of a report but the actual disclosure itself. This type of document fits best under Regulatory Filings (RNS) as it is a compliance disclosure under SEBI regulations and does not constitute a full financial report or other specific filing types.
2020-11-09 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding compliance with Regulation 47(1)(b) of SEBI Listing Regulations, 2015. It mentions the attachment of newspaper publications of unaudited financial results for the quarter and half year ended September 30, 2020. The document itself is a brief compliance letter and does not contain the actual financial results or detailed financial statements. It serves as an announcement or notification of the publication of financial results rather than the report itself. The document length is only 1140 characters, which is quite short and consistent with an announcement rather than a full interim or quarterly report. Therefore, according to the MENU VS MEAL rule, this should be classified as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR).
2020-11-04 English
Investor Presentation
Interim / Quarterly Report Classification · 95% confidence The document is a press release and investor presentation from Neuland Laboratories Limited dated November 3, 2020. It announces the unaudited financial results for the quarter and half year ended September 30, 2020, including detailed financial highlights, management commentary, and operational metrics. It also includes an invitation to an earnings call and a detailed presentation with financial data and business overview. The presence of detailed financial statements, management discussion, and forward-looking statements indicates this is a comprehensive interim financial report. The document is not merely an announcement of a report but contains substantive financial data and analysis for a period shorter than a full fiscal year (quarter and half year). Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2020-11-03 English
Press Release
Investor Presentation Classification · 95% confidence The document is a press release and investor presentation from Neuland Laboratories Limited dated November 3, 2020. It announces the unaudited financial results for the quarter and half year ended September 30, 2020, including detailed financial highlights, management commentary, operational metrics, and business overview. It also mentions an earnings call scheduled for the same day. The content includes detailed financial data such as income, EBITDA, PAT, margins, and EPS, as well as forward-looking statements and business strategy. This matches the characteristics of an Earnings Release (ER) combined with an Investor Presentation (IP). However, since the document includes detailed financial results and a presentation format, it fits best under the category of Investor Presentation (IP), which typically includes financials, strategy, and market position. The document is not merely a brief earnings announcement but a comprehensive presentation for investors. Therefore, the appropriate classification is Investor Presentation (IP).
2020-11-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.